Aceros, H.; Farah, G.; Cobos-Puc, L.; Stabile, Angelita Maria 
; Noiseux, N.; Mukaddam-Daher, S.
Source: British Journal of Pharmacology. Unidade: EERP
Subjects: APOPTOSE, CITOCINAS, HIPERTROFIA VENTRICULAR ESQUERDA, ECOCARDIOGRAFIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ACEROS, H. et al. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and AKT. British Journal of Pharmacology, v. 164, n. 3, p. 946-957, 2011Tradução . . Disponível em: https://doi.org/10.1111/j.1476-5381.2011.01355.x. Acesso em: 01 nov. 2024.APA
Aceros, H., Farah, G., Cobos-Puc, L., Stabile, A. M., Noiseux, N., & Mukaddam-Daher, S. (2011). Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and AKT. British Journal of Pharmacology, 164( 3), 946-957. doi:10.1111/j.1476-5381.2011.01355.xNLM
Aceros H, Farah G, Cobos-Puc L, Stabile AM, Noiseux N, Mukaddam-Daher S. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and AKT [Internet]. British Journal of Pharmacology. 2011 ; 164( 3): 946-957.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1111/j.1476-5381.2011.01355.xVancouver
Aceros H, Farah G, Cobos-Puc L, Stabile AM, Noiseux N, Mukaddam-Daher S. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and AKT [Internet]. British Journal of Pharmacology. 2011 ; 164( 3): 946-957.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1111/j.1476-5381.2011.01355.x
